Anti-MCSP antibodies
The invention provides anti-MCSP antibodies and methods of using the same.
1. An isolated antibody that binds to human Melanoma chondroitin sulfate proteoglycan (MCSP) wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 16.
2. The antibody of claim 1 , further comprising (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.
3. An isolated antibody that binds to human Melanoma chondroitin sulfate proteoglycan (MCSP), wherein the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:13; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.
4. The antibody of claim 2 , comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 32; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31; or (c) a VH sequence as in (a) and a VL sequence as in (b).
5. The antibody of claim 4 , comprising a VH sequence of SEQ ID NO: 32.
6. The antibody of claim 4 , comprising a VL sequence of SEQ ID NO: 31.
7. The antibody of claim 4 , comprising a VH sequence of SEQ ID NO: 32 and a VL sequence of SEQ ID NO: 31.
8. An immunoconjugate comprising the antibody of claim 2 and a cytotoxic agent.
9. A pharmaceutical formulation comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.
10. The antibody of claim 2 , wherein the antibody is a monoclonal, humanized, or chimeric antibody.
11. The antibody of claim 2 , wherein the antibody is a full-length IgG class antibody.
12. The antibody of claim 11 , wherein the antibody has been glycoengineered to modify the oligosaccharides in the Fc region and wherein the antibody has increased ADCC effector function as compared to an non-glycoengineered antibody.
13. The antibody of claim 12 , wherein the Fc region has a reduced number of fucose residues as compared to the nonglycoengineered antibody.
14. The antibody of claim 12 , wherein the antibody has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to the non-glycoengineered antibody.
15. The antibody of claim 12 , wherein the Fc region has an increased proportion of bisected oligosaccharides as compared to the non-glycoengineered antibody.
16. The antibody of claim 7 , wherein the antibody is a monoclonal, humanized, or chimeric antibody.
17. The antibody of claim 7 , wherein the antibody is a full-length IgG class antibody.
18. The antibody of claim 17 , wherein the antibody has been glycoengineered to modify the oligosaccharides in the Fc region and wherein the antibody has increased ADCC effector function as compared to an non-glycoengineered antibody.
19. The antibody of claim 18 , wherein the Fc region has a reduced number of fucose residues as compared to the nonglycoengineered antibody.
20. The antibody of claim 18 , wherein the antibody has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to the non-glycoengineered antibody.
21. The antibody of claim 18 , wherein the Fc region has an increased proportion of bisected oligosaccharides as compared to the non-glycoengineered antibody.